Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Breast cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,850 result(s) found for: Breast cancer. Displaying page 9 of 93.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2009-015628-27 Sponsor Protocol Number: CAUY922A2109 Start Date*: 2010-08-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase Ib/II, multi-center, open-label study to evaluate the efficacy of AUY922 in combination with Trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer, that ha...
    Medical condition: locally advanced or metastatic HER2-positive breast cancer, that has progressed after or during at least one Trastuzumab-containing regimen
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) FR (Completed) GB (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-005433-35 Sponsor Protocol Number: DBCG 05 H Start Date*: 2005-11-30
    Sponsor Name:Danish Breast Cancer Cooperative Group (DBCG)
    Full Title: TRASTUZUMAB (HERCEPTIN) SOM ADJUVERENDE BEHANDLING AF PATIENTER MED TIDLIG OPERABEL HER2-POSITIV BRYSTKRÆFT – ET FASE IV-STUDIE
    Medical condition: Kvinder, som har modtaget definitiv kirurgi for histologisk verificeret operabel ikke-metastatisk HER2-positiv brystkræft stratificeret i gruppen med øget risiko i hht. DBCG´s retningslinier, og so...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10006204 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001212-44 Sponsor Protocol Number: GIM-4 Start Date*: 2005-07-27
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: Letrozole adjuvant therapy duration (LEAD)study: standard versus long treatment. A phase III study in postmenopausal women with early breast cancer
    Medical condition: Adjuvant therapy with letrozole after 2 or 3 years of tamoxifen for early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015238-31 Sponsor Protocol Number: M09TNM Start Date*: 2009-12-16
    Sponsor Name:NKI-AVL
    Full Title: RANDOMIZED PHASE II/III STUDY OF INDIVIDUALIZED NEOADJUVANT CHEMOTHERAPY IN ‘TRIPLE-NEGATIVE’ BREAST TUMORS
    Medical condition: Triple negative breast cancer treated with neoadjuvant chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003634-42 Sponsor Protocol Number: TRAS-LIQ-2004 Start Date*: 2007-12-17
    Sponsor Name:Klinikum der Universität München, Standort Großhadern
    Full Title: Prospective phase II trial using Capecitabine and Trastuzumab for therapy of female patients with cerebral metastasizing, HER2-overexpressing breast cancer
    Medical condition: CNS-metastasizing HER2-overexpressing breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female PT
    9.1 10006202 Breast cancer stage IV PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-005231-22 Sponsor Protocol Number: D931CC00001 Start Date*: 2022-09-02
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Multicentre, Open-Label Study to Assess the Efficacy and Safety of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination as Neoadjuvant Therapy in Patients with BRCA Mutations a...
    Medical condition: BRCA Mutations and Early Stage HER2-Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Restarted) DE (Ongoing) AT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000174-37 Sponsor Protocol Number: GEICAM/2011-03_S1007 Start Date*: 2012-04-26
    Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)
    Full Title: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Re...
    Medical condition: Patients with confirmed diagnosis of node positive (1-3 nodes) invasive breast carcinoma with positive hormone receptor status, and negative HER-2.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000224-13 Sponsor Protocol Number: A6181100 Start Date*: 2006-05-10
    Sponsor Name:PFIZER AB
    Full Title: EXPLORATORY EVALUATION OF A SEQUENTIAL ADMINISTRATION OF DOCETAXEL AND SU011248 IN WOMEN WITH ADVANCED BREAST CANCER
    Medical condition: Advanced Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.0 10006187 PT
    Population Age: Gender:
    Trial protocol: SE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-005186-31 Sponsor Protocol Number: 01062017 Start Date*: 2018-06-06
    Sponsor Name:Department of Plastic Surgery, Breast and Burns Treatment
    Full Title: Fat Grafting with Ex-Vivo Expanded Adipose-Derived Stem Cells for Breast Reconstruction Following Mastectomy
    Medical condition: This study will include patients with genetic predisposition to development of breast cancer, who are offered prophylactic bilateral skin-sparring mastectomy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10018065 - General disorders and administration site conditions 10071981 BRCA2 gene mutation PT
    20.0 10018065 - General disorders and administration site conditions 10071980 BRCA1 gene mutation PT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-002286-30 Sponsor Protocol Number: A8641020 Start Date*: 2014-12-12
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: PHASE 2 STUDY OF SINGLE-AGENT PF 03084014 IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORS
    Medical condition: ADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORS
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended) IT (Completed) BE (Prematurely Ended) ES (Completed) DE (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003403-36 Sponsor Protocol Number: GEMCAPE Start Date*: 2005-11-10
    Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA
    Full Title: Trattamento con Capecitabina e Gemcitabina in pazienti con carcinoma della mammella metastatico pretrattati con Taxani ed Antracicline. Studio di fase II.
    Medical condition: BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    6.1 10055113 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-004860-22 Sponsor Protocol Number: IJB-BCTL:20120306 Start Date*: 2014-01-16
    Sponsor Name:Institute Jules Bordet
    Full Title: The [PEARL] Study : Pet imaging as a biomarker of Everolimus Added value in hormone Refractory postmenopausaL women
    Medical condition: Locally advanced or metastatic endocrine receptor positive and HER2 negative breast cancer refractory to non-steroidal aromatase inhibitors (NSAI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004532-58 Sponsor Protocol Number: LA-EP06-301 Start Date*: 2012-08-20
    Sponsor Name:Sandoz GmbH
    Full Title: A randomized, double-blind, parallel-group, multi-center Phase 3 comparative study investigating efficacy and safety of LA-EP2006 and Neulasta® in breast cancer patients treated with myelosuppressi...
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10006203 Breast cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-004189-13 Sponsor Protocol Number: 1 Start Date*: 2012-02-23
    Sponsor Name:Medizinische Universität Wien
    Full Title: ASSESSMENT OF MULTIDRUG RESISTANCE IN BREAST CANCER AND LOW GRADE GLIOMA PATIENTS WITH [11C]TARIQUIDAR PET. A PILOT STUDY
    Medical condition: Prospective cohort diagnostic test accuracy study in 30 breast cancer patients scheduled for neoadjuvant chemotherapy (15 of which with Pgp-positive and 15 with Pgp-negative tumors) and 10 low grad...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10006153 Brain tumor LLT
    18.1 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005209-23 Sponsor Protocol Number: CA163139 Start Date*: 2008-03-21
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Randomized Phase II of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects with Triple Negative (ER, PR, Her2 negative) Locally Advanced non-resectable and/...
    Medical condition: BREAST CANCER, FIRST LINE
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Gender: Female
    Trial protocol: FR (Completed) AT (Completed) CZ (Completed) ES (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2016-004986-18 Sponsor Protocol Number: DS8201-A-U201 Start Date*: 2017-11-08
    Sponsor Name:Daiichi Sankyo Inc.
    Full Title: A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Who are Resistant or Refrac...
    Medical condition: Unresectable/metastatic breast cancer with HER2 positive expression
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020826 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003530-13 Sponsor Protocol Number: 18072011 Start Date*: 2011-12-20
    Sponsor Name:Brighton & Sussex University Hospitals NHS Trust
    Full Title: Randomised phase II window study of short-term preoperative treatment with the PI3K inhibitor GDC-0941 plus Anastrozole versus Anastrozole alone in patients with ER-positive primary breast cancer
    Medical condition: Primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006206 Breast carcinoma NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005161-12 Sponsor Protocol Number: OAS-12DOC-BIO Start Date*: 2015-10-22
    Sponsor Name:Oasmia Pharmaceutical AB
    Full Title: A multi-country, multicenter, randomized, open-label, parallel group study to assess the efficacy and safety of Docecal compared with Taxotere®
    Medical condition: adenocarcinoma of the breast
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003262-41 Sponsor Protocol Number: GO28509 Start Date*: 2013-05-16
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE II, RANDOMIZED STUDY OF PACLITAXEL WITH GDC-0941 VERSUS PACLITAXEL WITH PLACEBO IN PATIENTS WITH LOCALLY RECURRENT OR METASTATIC BREAST CANCER
    Medical condition: Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) AT (Completed) CZ (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-020966-34 Sponsor Protocol Number: ICORG10-05 Start Date*: 2010-08-06
    Sponsor Name:ICORG
    Full Title: A phase II neoadjuvant study assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Traztuzumab and Lapatinib) in Erb B2 positive breast cancer patients
    Medical condition: Her 2 positive locally advanced or primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 13:29:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA